Non-coding RNAs underlying chemoresistance in gastric cancer
Background Gastric cancer (GC) is a major health issue in the Western world. Current clinical imperatives for this disease include the identification of more effective biomarkers to detect GC at early stages and enhance the prevention and treatment of metastatic and chemoresistant GC. The advent of...
Gespeichert in:
| Veröffentlicht in: | Cellular oncology (Dordrecht) 2020-12, Vol.43 (6), p.961-988 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 988 |
|---|---|
| container_issue | 6 |
| container_start_page | 961 |
| container_title | Cellular oncology (Dordrecht) |
| container_volume | 43 |
| creator | Poursheikhani, Arash Bahmanpour, Zahra Razmara, Ehsan Mashouri, Ladan Taheri, Mohammad Morshedi Rad, Dorsa Yousefi, Hassan Bitaraf, Amirreza Babashah, Sadegh |
| description | Background
Gastric cancer (GC) is a major health issue in the Western world. Current clinical imperatives for this disease include the identification of more effective biomarkers to detect GC at early stages and enhance the prevention and treatment of metastatic and chemoresistant GC. The advent of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long-non coding RNAs (lncRNAs), has led to a better understanding of the mechanisms by which GC cells acquire features of therapy resistance. ncRNAs play critical roles in normal physiology, but their dysregulation has been detected in a variety of cancers, including GC. A subset of ncRNAs is GC-specific, implying their potential application as biomarkers and/or therapeutic targets. Hence, evaluating the specific functions of ncRNAs will help to expand novel treatment options for GC.
Conclusions
In this review, we summarize some of the well-known ncRNAs that play a role in the development and progression of GC. We also review the application of such ncRNAs in clinical diagnostics and trials as potential biomarkers. Obviously, a deeper understanding of the biology and function of ncRNAs underlying chemoresistance can broaden horizons toward the development of personalized therapy against GC. |
| doi_str_mv | 10.1007/s13402-020-00528-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2409641948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2409641948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-c25c3e5ec2e9c3008329d9c58bb6531a52cb7ee2fb35d8334e0779e0bfb3f80c3</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EolXpD7BAWbIx2GM7iSU2VcVLqoqEYG0lzqSkyqPYyaJ_j0tKl8xmXneuNIeQa87uOGPJvedCMqAMGGVMQUrhjEwBOKdCivj8VEM6IXPvtyyEjHms4ksyESC1Ai2n5GHdtdR2RdVuovf1wkdDW6Cr94fefmHTOfSV77PWYlS10SbzvatsZA8Dd0Uuyqz2OD_mGfl8evxYvtDV2_PrcrGiVsikpxaUFajQAmorGEsF6EJbleZ5rATPFNg8QYQyF6pIhZDIkkQjy8OgTJkVM3I7-u5c9z2g701TeYt1nbXYDd6AZDqWXMs0SGGUWtd577A0O1c1mdsbzswBnBnBmQDO_IIzEI5ujv5D3mBxOvnDFARiFPiwajfozLYbXBt-_s_2B4wLd78</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2409641948</pqid></control><display><type>article</type><title>Non-coding RNAs underlying chemoresistance in gastric cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Poursheikhani, Arash ; Bahmanpour, Zahra ; Razmara, Ehsan ; Mashouri, Ladan ; Taheri, Mohammad ; Morshedi Rad, Dorsa ; Yousefi, Hassan ; Bitaraf, Amirreza ; Babashah, Sadegh</creator><creatorcontrib>Poursheikhani, Arash ; Bahmanpour, Zahra ; Razmara, Ehsan ; Mashouri, Ladan ; Taheri, Mohammad ; Morshedi Rad, Dorsa ; Yousefi, Hassan ; Bitaraf, Amirreza ; Babashah, Sadegh</creatorcontrib><description>Background
Gastric cancer (GC) is a major health issue in the Western world. Current clinical imperatives for this disease include the identification of more effective biomarkers to detect GC at early stages and enhance the prevention and treatment of metastatic and chemoresistant GC. The advent of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long-non coding RNAs (lncRNAs), has led to a better understanding of the mechanisms by which GC cells acquire features of therapy resistance. ncRNAs play critical roles in normal physiology, but their dysregulation has been detected in a variety of cancers, including GC. A subset of ncRNAs is GC-specific, implying their potential application as biomarkers and/or therapeutic targets. Hence, evaluating the specific functions of ncRNAs will help to expand novel treatment options for GC.
Conclusions
In this review, we summarize some of the well-known ncRNAs that play a role in the development and progression of GC. We also review the application of such ncRNAs in clinical diagnostics and trials as potential biomarkers. Obviously, a deeper understanding of the biology and function of ncRNAs underlying chemoresistance can broaden horizons toward the development of personalized therapy against GC.</description><identifier>ISSN: 2211-3428</identifier><identifier>EISSN: 2211-3436</identifier><identifier>DOI: 10.1007/s13402-020-00528-2</identifier><identifier>PMID: 32495294</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animals ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Cell Cycle - genetics ; Drug Resistance, Neoplasm - genetics ; Epithelial-Mesenchymal Transition - genetics ; Humans ; MicroRNAs - genetics ; MicroRNAs - metabolism ; Oncology ; Pathology ; Review ; RNA, Untranslated - genetics ; RNA, Untranslated - metabolism ; Stomach Neoplasms - genetics</subject><ispartof>Cellular oncology (Dordrecht), 2020-12, Vol.43 (6), p.961-988</ispartof><rights>International Society for Cellular Oncology 2020</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-c25c3e5ec2e9c3008329d9c58bb6531a52cb7ee2fb35d8334e0779e0bfb3f80c3</citedby><cites>FETCH-LOGICAL-c347t-c25c3e5ec2e9c3008329d9c58bb6531a52cb7ee2fb35d8334e0779e0bfb3f80c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13402-020-00528-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13402-020-00528-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32495294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Poursheikhani, Arash</creatorcontrib><creatorcontrib>Bahmanpour, Zahra</creatorcontrib><creatorcontrib>Razmara, Ehsan</creatorcontrib><creatorcontrib>Mashouri, Ladan</creatorcontrib><creatorcontrib>Taheri, Mohammad</creatorcontrib><creatorcontrib>Morshedi Rad, Dorsa</creatorcontrib><creatorcontrib>Yousefi, Hassan</creatorcontrib><creatorcontrib>Bitaraf, Amirreza</creatorcontrib><creatorcontrib>Babashah, Sadegh</creatorcontrib><title>Non-coding RNAs underlying chemoresistance in gastric cancer</title><title>Cellular oncology (Dordrecht)</title><addtitle>Cell Oncol</addtitle><addtitle>Cell Oncol (Dordr)</addtitle><description>Background
Gastric cancer (GC) is a major health issue in the Western world. Current clinical imperatives for this disease include the identification of more effective biomarkers to detect GC at early stages and enhance the prevention and treatment of metastatic and chemoresistant GC. The advent of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long-non coding RNAs (lncRNAs), has led to a better understanding of the mechanisms by which GC cells acquire features of therapy resistance. ncRNAs play critical roles in normal physiology, but their dysregulation has been detected in a variety of cancers, including GC. A subset of ncRNAs is GC-specific, implying their potential application as biomarkers and/or therapeutic targets. Hence, evaluating the specific functions of ncRNAs will help to expand novel treatment options for GC.
Conclusions
In this review, we summarize some of the well-known ncRNAs that play a role in the development and progression of GC. We also review the application of such ncRNAs in clinical diagnostics and trials as potential biomarkers. Obviously, a deeper understanding of the biology and function of ncRNAs underlying chemoresistance can broaden horizons toward the development of personalized therapy against GC.</description><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Cell Cycle - genetics</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Epithelial-Mesenchymal Transition - genetics</subject><subject>Humans</subject><subject>MicroRNAs - genetics</subject><subject>MicroRNAs - metabolism</subject><subject>Oncology</subject><subject>Pathology</subject><subject>Review</subject><subject>RNA, Untranslated - genetics</subject><subject>RNA, Untranslated - metabolism</subject><subject>Stomach Neoplasms - genetics</subject><issn>2211-3428</issn><issn>2211-3436</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EolXpD7BAWbIx2GM7iSU2VcVLqoqEYG0lzqSkyqPYyaJ_j0tKl8xmXneuNIeQa87uOGPJvedCMqAMGGVMQUrhjEwBOKdCivj8VEM6IXPvtyyEjHms4ksyESC1Ai2n5GHdtdR2RdVuovf1wkdDW6Cr94fefmHTOfSV77PWYlS10SbzvatsZA8Dd0Uuyqz2OD_mGfl8evxYvtDV2_PrcrGiVsikpxaUFajQAmorGEsF6EJbleZ5rATPFNg8QYQyF6pIhZDIkkQjy8OgTJkVM3I7-u5c9z2g701TeYt1nbXYDd6AZDqWXMs0SGGUWtd577A0O1c1mdsbzswBnBnBmQDO_IIzEI5ujv5D3mBxOvnDFARiFPiwajfozLYbXBt-_s_2B4wLd78</recordid><startdate>20201201</startdate><enddate>20201201</enddate><creator>Poursheikhani, Arash</creator><creator>Bahmanpour, Zahra</creator><creator>Razmara, Ehsan</creator><creator>Mashouri, Ladan</creator><creator>Taheri, Mohammad</creator><creator>Morshedi Rad, Dorsa</creator><creator>Yousefi, Hassan</creator><creator>Bitaraf, Amirreza</creator><creator>Babashah, Sadegh</creator><general>Springer Netherlands</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20201201</creationdate><title>Non-coding RNAs underlying chemoresistance in gastric cancer</title><author>Poursheikhani, Arash ; Bahmanpour, Zahra ; Razmara, Ehsan ; Mashouri, Ladan ; Taheri, Mohammad ; Morshedi Rad, Dorsa ; Yousefi, Hassan ; Bitaraf, Amirreza ; Babashah, Sadegh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-c25c3e5ec2e9c3008329d9c58bb6531a52cb7ee2fb35d8334e0779e0bfb3f80c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Cell Cycle - genetics</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Epithelial-Mesenchymal Transition - genetics</topic><topic>Humans</topic><topic>MicroRNAs - genetics</topic><topic>MicroRNAs - metabolism</topic><topic>Oncology</topic><topic>Pathology</topic><topic>Review</topic><topic>RNA, Untranslated - genetics</topic><topic>RNA, Untranslated - metabolism</topic><topic>Stomach Neoplasms - genetics</topic><toplevel>online_resources</toplevel><creatorcontrib>Poursheikhani, Arash</creatorcontrib><creatorcontrib>Bahmanpour, Zahra</creatorcontrib><creatorcontrib>Razmara, Ehsan</creatorcontrib><creatorcontrib>Mashouri, Ladan</creatorcontrib><creatorcontrib>Taheri, Mohammad</creatorcontrib><creatorcontrib>Morshedi Rad, Dorsa</creatorcontrib><creatorcontrib>Yousefi, Hassan</creatorcontrib><creatorcontrib>Bitaraf, Amirreza</creatorcontrib><creatorcontrib>Babashah, Sadegh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cellular oncology (Dordrecht)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poursheikhani, Arash</au><au>Bahmanpour, Zahra</au><au>Razmara, Ehsan</au><au>Mashouri, Ladan</au><au>Taheri, Mohammad</au><au>Morshedi Rad, Dorsa</au><au>Yousefi, Hassan</au><au>Bitaraf, Amirreza</au><au>Babashah, Sadegh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Non-coding RNAs underlying chemoresistance in gastric cancer</atitle><jtitle>Cellular oncology (Dordrecht)</jtitle><stitle>Cell Oncol</stitle><addtitle>Cell Oncol (Dordr)</addtitle><date>2020-12-01</date><risdate>2020</risdate><volume>43</volume><issue>6</issue><spage>961</spage><epage>988</epage><pages>961-988</pages><issn>2211-3428</issn><eissn>2211-3436</eissn><abstract>Background
Gastric cancer (GC) is a major health issue in the Western world. Current clinical imperatives for this disease include the identification of more effective biomarkers to detect GC at early stages and enhance the prevention and treatment of metastatic and chemoresistant GC. The advent of non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs) and long-non coding RNAs (lncRNAs), has led to a better understanding of the mechanisms by which GC cells acquire features of therapy resistance. ncRNAs play critical roles in normal physiology, but their dysregulation has been detected in a variety of cancers, including GC. A subset of ncRNAs is GC-specific, implying their potential application as biomarkers and/or therapeutic targets. Hence, evaluating the specific functions of ncRNAs will help to expand novel treatment options for GC.
Conclusions
In this review, we summarize some of the well-known ncRNAs that play a role in the development and progression of GC. We also review the application of such ncRNAs in clinical diagnostics and trials as potential biomarkers. Obviously, a deeper understanding of the biology and function of ncRNAs underlying chemoresistance can broaden horizons toward the development of personalized therapy against GC.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>32495294</pmid><doi>10.1007/s13402-020-00528-2</doi><tpages>28</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2211-3428 |
| ispartof | Cellular oncology (Dordrecht), 2020-12, Vol.43 (6), p.961-988 |
| issn | 2211-3428 2211-3436 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2409641948 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Animals Biomedical and Life Sciences Biomedicine Cancer Research Cell Cycle - genetics Drug Resistance, Neoplasm - genetics Epithelial-Mesenchymal Transition - genetics Humans MicroRNAs - genetics MicroRNAs - metabolism Oncology Pathology Review RNA, Untranslated - genetics RNA, Untranslated - metabolism Stomach Neoplasms - genetics |
| title | Non-coding RNAs underlying chemoresistance in gastric cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T17%3A33%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Non-coding%20RNAs%20underlying%20chemoresistance%20in%20gastric%20cancer&rft.jtitle=Cellular%20oncology%20(Dordrecht)&rft.au=Poursheikhani,%20Arash&rft.date=2020-12-01&rft.volume=43&rft.issue=6&rft.spage=961&rft.epage=988&rft.pages=961-988&rft.issn=2211-3428&rft.eissn=2211-3436&rft_id=info:doi/10.1007/s13402-020-00528-2&rft_dat=%3Cproquest_cross%3E2409641948%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2409641948&rft_id=info:pmid/32495294&rfr_iscdi=true |